- Home
- TURN vs AKTX Comparison
TURN vs AKTX Comparison
Compare TURN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- AKTX
- Stock Information
- Founded
- TURN 1981
- AKTX N/A
- Country
- TURN United States
- AKTX United States
- Employees
- TURN 8
- AKTX N/A
- Industry
- TURN Finance/Investors Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- AKTX Health Care
- Exchange
- TURN Nasdaq
- AKTX Nasdaq
- Market Cap
- TURN 33.3M
- AKTX 29.5M
- IPO Year
- TURN N/A
- AKTX N/A
- Fundamental
- Price
- TURN $3.33
- AKTX $2.08
- Analyst Decision
- TURN
- AKTX
- Analyst Count
- TURN 0
- AKTX 0
- Target Price
- TURN N/A
- AKTX N/A
- AVG Volume (30 Days)
- TURN 21.5K
- AKTX 15.6K
- Earning Date
- TURN 11-26-2024
- AKTX 11-26-2024
- Dividend Yield
- TURN N/A
- AKTX N/A
- EPS Growth
- TURN N/A
- AKTX N/A
- EPS
- TURN N/A
- AKTX N/A
- Revenue
- TURN $129,297.00
- AKTX N/A
- Revenue This Year
- TURN N/A
- AKTX N/A
- Revenue Next Year
- TURN N/A
- AKTX N/A
- P/E Ratio
- TURN N/A
- AKTX N/A
- Revenue Growth
- TURN 6.32
- AKTX N/A
- 52 Week Low
- TURN $3.12
- AKTX $1.08
- 52 Week High
- TURN $4.47
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- TURN 52.80
- AKTX 34.80
- Support Level
- TURN $3.23
- AKTX $2.21
- Resistance Level
- TURN $3.36
- AKTX $2.40
- Average True Range (ATR)
- TURN 0.09
- AKTX 0.28
- MACD
- TURN 0.01
- AKTX -0.00
- Stochastic Oscillator
- TURN 76.47
- AKTX 20.15
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).